Radiopharm Theranostics Limited (RADX)
Radiopharm Theranostics Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Radiopharm Theranostics Limited (RADX) is a Biotechnology company based in AU with a market capitalization of $5.5M. Revenue grew 1114.3% year-over-year and free cash flow was negative at -$25.4M. This page tracks RADX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
AU · 14 employees · IPO Dec 5, 2024
Valuation
Valuation & price
$4.71as of May 17, 2026· -55.7% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.12
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$5.5M
Market cap
1114.3%
Revenue growth (YoY)
1.1%
Gross margin
-$25.4M
Free cash flow (USD)
-$29.1M
Net debt
Net cash position
438.5%
Share dilution
2/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2022 → 2025
Free cash flow by year
2022 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed Jul 22, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 24, 2026Filing
Capital Raise
- Quarterly reportJul 22, 2026Filing
Interim Results (6-K)
- 6-K filingJul 6, 2026Filing
R&D Tax Incentive Received
- 6-K filingJun 30, 2026Filing
Notification of Securities
- 6-K filingJun 3, 2026Filing
Notification of Cessation of Securities
- 6-K filingMay 1, 2026Filing
Financial Services and Company Secretary Changes
- Annual reportApr 23, 2026Filing
Annual Report Filed
- 6-K filingApr 20, 2026Filing
Initial Findings from Phase 1 Trial
- 6-K filingApr 16, 2026Filing
Clinical Trial Enrollment Completed
- 6-K filingApr 8, 2026Filing
Clinical Trial Update
Questions
Frequently asked questions
What is Radiopharm Theranostics Limited's market cap?
Radiopharm Theranostics Limited (RADX) has a market capitalization of $5.5M.
What is RADX's P/E ratio?
A meaningful P/E ratio is not available for RADX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is RADX's price-to-book (P/B) ratio?
RADX trades at 0.12 times book value per share.
Are insiders buying RADX stock?
SEC Form 4 filings show no open-market insider buys at Radiopharm Theranostics Limited in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.